Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer (NCT05300958) | Clinical Trial Compass
TerminatedPhase 2
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Stopped: Difficulty accruing subjects the study accrual was closed.
China25 participantsStarted 2022-03-21
Plain-language summary
The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.
Who can participate
Age range18 Years – 70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria.
* Fail second-line or above anti-tumor treatment
* Evaluation is stable disease with a trend of progression.
* Minimum life expectancy 16 weeks
* Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis
* ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks
* Normal organ function.
* Has signed a Patient Informed Consent Form.
Exclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) score of ≥ 2
* Patients with severe liver and kidney insufficiency
* Deferoxamine Ingredients allergy
* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment
* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication
* Researchers consider it is not suitable for participation.